LGI1-AE Outcomes Predicted by Relapse Burden and Treated with Rituximab

In partnership with Medscape, ESO invites you to explore "Preventing the Next Stroke: Factor XI(a) Inhibition – From Evidence to Practice." Upon completion of this activity, participants will: 🔹Have increased knowledge regarding the pharmacologic rationale for targeting factor XI/XIa to prevent thrombosis 🔹Clinical evidence for factor XIa inhibitors in secondary stroke prevention 🔹Clinical profiles of patients who may benefit from factor XIa inhibition 🔹Demonstrate greater confidence in their ability to recall the potential role of factor XIa inhibitors in future clinical practice 🎓 Chair: Ashkan Shoamanesh 🎓 Panelists: Valeria Caso & Thalia Field Take part in this free online CME activity and enhance your clinical practice with the latest evidence.🔗 https://ow.ly/ZMBF50ZrP2e. ✅ Earn 1 CME Credit / 1 ABIM MOC Point #Stroke #StrokePrevention #Neurology #MedicalEducation #CME Medscape Education

Your mid-stage PD patient is stiff and slow—and depressed. Medication alone isn't cutting it. What's left? 𝐌𝟏-𝐢𝐓𝐁𝐒 𝐢𝐧 𝐌𝐢𝐝-𝐒𝐭𝐚𝐠𝐞 𝐏𝐃 (2026, Neurotherapeutics) tested exactly that. 𝐖𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐟𝐨𝐮𝐧𝐝: • 𝐌𝐨𝐭𝐨𝐫 𝐬𝐜𝐨𝐫𝐞𝐬 𝐝𝐫𝐨𝐩𝐩𝐞𝐝 𝟑𝟎.𝟕% 𝐰𝐢𝐭𝐡 𝐫𝐞𝐚𝐥 𝐢𝐓𝐁𝐒 𝐯𝐬 𝟏𝟒.𝟑% 𝐰𝐢𝐭𝐡 𝐬𝐡𝐚𝐦 (p=0.036) • Depression fell 47.6%; anxiety dropped 37.9% • Responders showed strengthened brain connectivity between cerebellum, thalamus, and motor cortex 𝐁𝐨𝐭𝐭𝐨𝐦 𝐥𝐢𝐧𝐞: Five days of bilateral motor cortex stimulation produced clinically meaningful motor and mood gains in mid-stage disease. Have you considered noninvasive brain stimulation for your PD patients when meds plateau? Read the full trial summary on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/eMv2d8fc #NeuroTrials #Neurology #ClinicalTrials #Parkinsons #MovementDisorders

Your AF patient just got a stent. Twelve months of dual therapy — or one? 𝐎𝐏𝐓𝐈𝐌𝐀-𝐀𝐅 (2026, The Lancet) tested exactly that. 𝐖𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐟𝐨𝐮𝐧𝐝: • 1 month of DOAC + P2Y12, then DOAC alone: non-inferior for death or thromboembolism • 𝐌𝐚𝐣𝐨𝐫 𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐫𝐞𝐥𝐞𝐯𝐚𝐧𝐭 𝐛𝐥𝐞𝐞𝐝𝐢𝐧𝐠 𝐡𝐚𝐥𝐯𝐞𝐝 (4.5% vs 8.8%) • Efficacy superiority not shown — event rates ran lower than expected 𝐁𝐨𝐭𝐭𝐨𝐦 𝐥𝐢𝐧𝐞: Earlier switch to DOAC monotherapy cuts bleeding without clear loss of protection; interpret efficacy cautiously. How soon do you drop the antiplatelet after PCI in your AF patients? Read the full trial summary on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/enrE-6MF #NeuroTrials #Neurology #ClinicalTrials #Stroke #StrokeResearch

Open Access: Autonomic dysfunction in spontaneous intracranial hypotension: How common is it? Orthostatic symptoms are a hallmark of spontaneous intracranial hypotension (SIH), but do they reflect underlying autonomic dysfunction? In this cross-sectional study, investigators performed comprehensive autonomic testing in patients with imaging-confirmed SIH due to dural tears. Key findings: 🩺 More than half of patients demonstrated orthostatic autonomic dysfunction. ❤️ Postural orthostatic tachycardia syndrome (POTS) was the most common orthostatic abnormality, followed by orthostatic hypotension. 🔬 Abnormalities were also identified in cardiovagal and sudomotor function. 📊 Autonomic dysfunction was not associated with specific clinical or imaging features, suggesting it may represent an important but independent aspect of SIH. These findings highlight the value of considering autonomic function in patients with SIH and add to our understanding of the mechanisms underlying orthostatic symptoms in this condition. Read the full article: https://lnkd.in/gamgb8WA Woo-Seok Ha MD, Da Eun Jung MD, Sojung Yoon MD, Joonho Kim MD, PhD, Min Kyung Chu MD, PhD #SpontaneousIntracranialHypotension #SIH #POTS #Neurology

Continuous education drives better stroke care. We are pleased to support this PeerVoice educational activity, which brings together expert insights into the evolving evidence on investigational Factor XIa inhibition for secondary stroke prevention. WATCH NOW: https://lnkd.in/en2aSJju #Stroke #StrokePrevention #FXIa #Neurology #MedEd PeerVoice

A key distinction in MS treatment: unlike most neurological diseases, therapies for multiple sclerosis primarily target the immune system rather than the affected organ — the brain. At #CMSC2026, Ahmed Obeidat, MD, PhD, of Medical College of Wisconsin, unpacks this concept in a new video interview with NeurologyLive. 🎥 Watch this conversation and explore more CMSC 2026 coverage: https://hubs.li/Q04pWbPT0 #MultipleSclerosis #Neurology #MedicalEducation #CMSC #MSCare CMSC International Journal of MS Care (IJMSC)

Open Access: Can early clinical features predict epidural blood patch success in intracranial hypotension syndrome? A recent study examined 139 epidural blood patch (EBP) procedures to identify factors associated with sustained treatment response in patients with intracranial hypotension syndrome. Key findings: • 31% of procedures resulted in complete symptom resolution or marked improvement at 1 month. • Early improvement within 48 hours was strongly associated with successful outcomes at 1 month. • Rebound headache after EBP was also associated with greater likelihood of long-term success. • Valsalva-related symptom worsening predicted a lower likelihood of durable benefit. • Imaging severity did not independently predict treatment success. These findings suggest that readily identifiable clinical features following EBP may help guide follow-up, counseling, and decisions about repeat procedures. 📖 Read the article: https://lnkd.in/gWp7iX86 Anna Le Moal-Baczynski MD, Alexandre Castelli MD, Vincent Doat-Sarfati MD, Sylvain REDON MD, Anne Donnet MD, Nicolas Bruder MD, PhD, Francois Antonini MD, Jules Henri MD, Jean-François HAK MD, PhD, @Victor Lebreton MD, Jeanne Morel MD, Mehdi Assal MD, Velly Lionel MD, PhD, Pierre Simeone MD, PhD #Neurology #SIH #IntracranialHypotension #EpiduralBloodPatch

🧬 Gene-silencing therapies, particularly vutrisiran and patisiran, demonstrate superior efficacy over older pharmacological interventions in improving neuropathy impairment and quality of life in hereditary transthyretin-related amyloidosis with polyneuropathy (ATTRv-PN), although these findings should be regarded as hypothesis-generating given the scarcity of data, lack of head-to-head trials, and clinical heterogeneity across trials. 📚 Read the recently published article "Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis" by Duarte et al.: https://buff.ly/3B4ZX1E European Academy of Neurology #WileyNeuro #Amyloidosis #Neuropathy #Neuromuscular #Neurology

Stroke care continues to evolve, with growing emphasis not only on acute intervention but also on supporting neurological recovery. Recently, I explored Tyvalzi™ (Sovateltide), a novel adjunctive therapy approved in India for acute ischemic stroke. Its unique mechanism and potential role in promoting neurological recovery make it an interesting development in the evolving landscape of stroke management. In this carousel, I have briefly covered: ✔️ The burden of acute ischemic stroke ✔️ The need for improved recovery strategies ✔️ Tyvalzi™ (Sovateltide) and its mechanism of action ✔️ Administration protocol ✔️ Key insights from published clinical studies As research continues to advance, therapies that focus on recovery and functional outcomes may play an increasingly important role in shaping the future of stroke care. #StrokeCare #AcuteIschemicStroke #Neurology #ClinicalResearch #Sovateltide #Tyvalzi #Pharmacotherapy #PatientCare #HealthcareInnovation

Deep Brain Stimulation continues to play an important role in the management of selected patients with Parkinson's disease, tremor and dystonia. We are proud to see Cleveland Clinic London's neurology and neurosurgery teams expand access to this advanced therapy.